First AI-Designed Drug Improves IPF Lung Function
Insilico Medicine reports its investigational SM001-055 - the first drug designed using generative AI - had encouraging topline results in a phase 2A clinical trial.
A global clinical stage biotechnology company powered by generative AI, Insilico Medicine is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
At-a-Glance
Insilico's Pharma.AI platform provides end-to-end drug discovery and development services, including target discovery, novel drug design, and clinical trial outcome prediction and optimization.
The platform was used to develop Insilico's internal pipeline of 31 programs across 29 drug targets, five of which are clinical stage, and one, ISM001-055 for idiopathic pulmonary fibrosis (IPF), which is in Phase II trials.
Insilico is a global organization with headquarters in New York City and Hong Kong, and offices and labs in Montreal, Shanghai, Suzhou, and Abu Dhabi.
